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Macrophageslves interaction of Env with CD4 and a chemokine coreceptor, either CCR5 or
CXCR4. Other cellular factors supporting HIV replication have also been characterized. We previously
demonstrated a role for CD63 in early HIV infection events in macrophages via inhibition by anti-CD63
antibody pretreatment. To conﬁrm the requirement for CD63 in HIV replication, we decreased CD63
expression using CD63-speciﬁc short interfering RNAs (siRNA), and showed inhibition of HIV replication in
macrophages. Surprisingly, pretreatment with CD63 siRNA not only silenced CD63 expression by 90%, but
also inhibited HIV-1 replication in a cultured cell line (U373-MAGI) which had been previously shown to be
insensitive to CD63 monoclonal antibody inhibition. Although the anti-CD63 antibody was previously shown
to inhibit early HIV infection events only in macrophages, we now show a potential role for CD63 in later HIV
replication events in macrophages and cell lines. Further delineation of the role of CD63 in HIV replication
may lead to development of novel therapeutic compounds.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) replication has
been shown to extensively utilize cellular factors. A recent large-scale
siRNA screen revealed over 250 candidate host factors which may aid
successive steps in the viral replication cycle (Brass et al., 2008).
Infection is initiated by high afﬁnity Env binding to CD4 (Klatzmann et
al., 1984) followed by interaction with chemokine receptors, either
CCR5 or CXCR4 (Dragic et al., 1996; Feng et al., 1996). Reverse
transcription is largely independent of cellular enzymes or cofactors,
but HIV integration and proviral transcription require participation of
host cell factors (Goodarzi et al., 1999; Greene, 1991). Following viral
gene expression, the cellular GTPase Rab9 facilitates trafﬁcking of viral
proteins from the late endosome to the trans-Golgi (Murray et al.,
2005). Rab9 appears to play a role in the replication of several different
viruses, including HIV. Finally, a set of protein complexes, the
Endosomal Sorting Complexes Required for Transport (ESCRTs), are
required to arrange viral proteins for assembly of several RNA viruses,
perhaps best established for retroviruses (Morita et al., 2004; Pelchen-al Branch at Galveston, 301
ax: +1 409 772 6527.
).
l rights reserved.Matthews et al., 2004). Until last year, all antiviral treatments targeted
viral proteins, butmoving forward the ﬁrst antiviral drug that targets a
cellular gene (CCR5) has been approved by the FDA, maraviroc
(Selzentry), which marks the beginning of a new era; like CCR5, CD63
is another cellular protein that may represent an important new
therapeutic target for the development of antiretroviral drugs.
Tetraspanins cross the plasma membrane with four transmem-
brane domains and potentially serve critical roles in HIV-1 replication.
These integral membrane proteins are ubiquitously expressed in
human cells. We previously showed that anti-CD63 monoclonal
antibody (mAb) treatment 30 min prior to and during infection
markedly reduced HIV replication in macrophages, but not in primary
T cells or cell lines (von Lindern et al., 2003). Inhibition was shown to
occur during early infection prior to initiation of reverse transcription,
suggestive of involvement in virus entry or uncoating. CD63 closely
associates with other integral membrane proteins, the β-2 integrins,
as well as other tetraspanins (Hammond et al., 1998; Mannion et al.,
1996; Rubinstein et al., 1996), and it is possible that CD63 antibody
treatment may interfere with post-viral binding effects in macro-
phages, including signal transduction or viral uptake. CD63 and other
tetraspanins are also known to form discrete membrane regions
termed tetraspan enriched microdomains (TEMs), although only
limited data are available to support a role for TEMs in viral
replication. CD63 is particularly abundant in endosomes, which are
involved in virion production (Ono et al., 2004; Kramer et al., 2005;
Fig. 2. Inhibition of HIV-SF162 (R5) infection after CD63 down regulation in
macrophages. Macrophages were puriﬁed by adherence to plastic, and were treated
with siRNA on day 5 (A) or on day 10 (B). In either case, cells (4×105) were infected with
HIV-SF162 (R5) on day 7 using an MOI of 0.02 and extracellular virus was measured in
the cultured supernatant 7 days post-infection by p24 ELISA. ⁎Pb0.05, compared with
CD63 siRNA group.
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found in HIV virions, and may incorporate into nascent virions as HIV
buds from endosomal structures or plasma membrane regions rich in
CD63 and other tetraspanins (Pelchen-Matthews et al., 2003).
Although CD63 appears to play a role in HIV entry of macrophages,
but not T cells, there may be an additional role for CD63 in later steps
of virus replication. Here, we describe a potential role for CD63 in both
primary macrophages and CD4+ cell lines, demonstrated by showing
decreased HIV replication in cells following CD63 down regulation by
RNA interference (RNAi) with short interfering RNA (siRNA).
Results
CD63 down regulation by siRNA in macrophages
To conﬁrm the role of CD63 in HIV replication in primary
macrophages, we optimized siRNA transfections of these cells for
RNAi studies. By Western dot-blot analysis, CD63 is barely detectable
at 24 h and was not observed at 48 h (Fig. 1), whereas CD63
expression was unaffected in control siRNA-transfected or untrans-
fected cells relative to β-actin controls. To gauge the effect of CD63
down regulation on HIV replication, macrophages were transfected
with various speciﬁc siRNAs or scrambled control siRNA after 5 to
7 days of adherence. They were infected 48 h later with the R5
strain HIV-SF162 and virus production was assessed in culture
supernatant by p24 ELISA after 7 days. Virus production was
signiﬁcantly reduced following transfection with siRNA speciﬁc for
CD4, CCR5 or CD63, but there was no effect on virus production
following CXCR4-speciﬁc siRNA transfection or that of scrambled
control siRNA (Fig. 2A).
CD63 down regulation after HIV infection in macrophages
In order to determine if CD63 plays a role in later events in HIV
replication, macrophages were transfected with control, CD63, or
CD4, or HIV coreceptor-speciﬁc siRNAs 3 days post-infection (Fig. 2B).
Treatment with CD4-speciﬁc siRNA 3 days after infection did not
signiﬁcantly affect virus production, but virus production was still
inhibited when CD63-speciﬁc siRNA treatment was initiated 3 days
after infection, suggesting an important role for CD63 in macro-
phages during HIV replication events occurring after proviral
integration.Fig. 1. Down regulation of CD63 in macrophages by RNAi. Following adherence for
6 days, macrophages (4×105 per well in 24-well plates) were transfected with 100 nM
CD63-speciﬁc siRNA for 24 or 48 h using oligofectamine. Scrambled siRNA and
untransfected cells were used as controls. Following transfection, cells were lysed in 1%
TritonX-100 in PBS and subjected toWestern dot-blot analysis with anti-CD63 antibody
or anti-β-actin antibody internal control for cellular protein.To further assess the role of CD63 in the late stage of HIV
replication, CD63-speciﬁc siRNA was transfected into U1/HIV-1 cells,
which are chronically infected monocytoid cells harboring 2
integrated copies of provirus per cell. Early steps of HIV replication
are not required for virus production in these cells, and virus
production can be induced with 3 phorbol 12-myristate 13-acetate
(PMA). HIV viral productionwas reduced in CD63-depleted U1 cells to
the same level as in cells treated with Rab 9-speciﬁc siRNA (Fig. 3),
which is involved in post-integration trafﬁcking of HIV proteins from
the late endosome to the trans-Golgi (Murray et al., 2005). We also
observed a decrease in virus production when we used JC53 CD4+
cells transfected with both CD63-speciﬁc siRNA followed by HIV-SX
plasmid (data not shown); these ﬁndings further support the role of
CD63 in later stages of HIV replication, speciﬁcally occurring after
proviral integration.Fig. 3. Inhibition of late stage of HIV replication in an HIV-producing cell line (U1/HIV)
depleted of CD63. U1/HIV-1 cells were plated (1×106) on day 1. Cells were transfected
with CD63- or Rab 9-speciﬁc siRNA, and on day 3 phorbol 12-myristate 13-acetate
(PMA) was added to induce virus expression. Extracellular virus was measured in the
culture supernatant on day 4 by p24 ELISA. ⁎Pb0.05, with CD63 siRNA compared to
virus (PMA) alone and control scrambled siRNA.
Fig. 4. Down regulation of CD63 in U373-MAGI-CCR5 by siRNA. U373-MAGI-CCR5 cells
were transfected 24 h or 48 h with 100 nM CD63-speciﬁc siRNA. Scrambled control
siRNA and untransfected cells were also included. Cells were lysed in 1% TritonX-100 in
PBS and subjected toWestern dot-blot analysis with anti-CD63 antibody or anti-β-actin
antibody internal control for cellular protein.
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Down regulation of CD63 by RNAi was assessed in the U373-MAGI-
CCR5 cell line. CD63 protein levels were reduced at 24 h and 48 h
following transfection of CD63-speciﬁc siRNA, as shownbyWesterndot-
blot analysis (Fig. 4). To assess surface expression of these molecules,
effects of siRNA treatment were also determined by ﬂow cytometry.
CD4-speciﬁc siRNA resulted inmodest reduction of CD4 expression (Fig.
5A), but speciﬁc expression was markedly reduced by both CCR5- and
CD63-speciﬁc siRNA treatment (Figs. 5B and C). Notably, CD63 siRNA
treatment did not affect expression of either CD4 or CCR5 (Fig. 5D).Fig. 5. CD4, CCR5 and CD63 levels on U373-MAGI-CCR5 24 h after siRNA transfection. U373-M
CD63 or scrambled control siRNAs. At 24 h post-transfection, cells were detached using 1× tr
CD63-PE antibody andmeasured by ﬂowcytometry. Levels of CD4, CCR5 and CD63 in control
was used to determine the rate of down regulation.Effect of CD63 down regulation on HIV replication in U373-MAGI cells
Replication of HIV-SF162 (R5; Fig. 6A) or HIV 89.6 (R5X4; Fig. 6B),
as determined by β-gal activity 3 days after infection, was reduced
following CD63 or CCR5 down regulation in U373-MAGI-CCR5 cells;
reduction was greater with CD4 down regulation (Figs. 6A and B).
Using a related indicator cell line, U373-MAGI-CXCR4 (Fig. 6C)
expressing the chemokine coreceptor CXCR4 and not CCR5, down
regulation of CD4, CD63 or CXCR4 signiﬁcantly reduced virus
replication, compared to transfection with scrambled or negative
control siRNAs (Fig. 6C); Pb0.05, compared with CD63 siRNA. As
expected, CCR5-speciﬁc siRNA treatment did not affect virus replica-
tion in these cells, since U373-MAGI-CXCR4 cells do not express CCR5
(Fig. 6C). Although the RLU of control siRNA-transfected cells was
higher than that of the untransfected cells in each case (Figs. 6A–C,
statistically there is no difference.
Discussion
CD63, a tetraspanin membrane glycoprotein found in nearly all
human cells on the plasma membrane and especially abundant in
endosomes, was previously shown to be involved in early events of
HIV replication in macrophages (von Lindern et al., 2003). In this
study, we present evidence for an expanded role of CD63 in HIV
replication, not only limited to early events, but also likely involving
later HIV replication events, in cell lines as well as in macrophages.
This effect was shown for infection of R5 and R5X4 viruses following
down regulation of CD63 by RNA interference with siRNA. Although
PBL and cell lines were resistant to inhibition of HIV infection by a
CD63 antibody, HIV replication in cell lines was inhibited following
down regulation of CD63.
There are important cell-speciﬁc differences between the entry
process in macrophages and cell lines or T cells that could explain
the lack of anti-CD63 antibody inhibition of HIV replication in U373-
MAGI cells or PBL. It is possible that this mode of entry may be more
important in phagocytic cells such as macrophages. CD63, which isAGI-CCR5 cells (5×104) were seeded in 24-well plates and transfected with CD4, CCR5,
ypsin and stained with (A) anti-CD4-PE antibody, (B) anti-CCR5-PE antibody, or (C) anti-
or CD63 siRNA transfectants are compared in panel (D). An IgG1 isotype antibody control
Fig. 6. Infection of U373-MAGI-CCR5 or U373-MAGI-CXCR4 30 h post-transfection of
siRNA. (A and B) U373-MAGI-CCR5 or (C) U373-MAGI-CXCR4 cells (104) were seeded in
96-well plates 24 h prior to transfection. Cells were transfected with CD4 siRNA, CCR5
siRNA, CD63 siRNA or scrambled control siRNA in quadruplicate. Transfection reagent
was included in the no siRNA transfection control. After 30 h, cells were infectedwith an
m.o.i. of approximately 0.02 with (A) HIV-SF162 (R5), or with (B) HIV-89.6 (R5X4). (C)
U373-MAGI-CXCR4 cells were infected with HIV-89.6 (R5X4). β-galactosidase activity
was measured by Beta-Glo™ Assay System (Promega) by luminometry performed 48 h
post-infection, with subtraction of signal from uninfected U373-MAGI cells. ⁎Pb0.05,
compared with CD63 siRNA group.
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in preventing degradation of the virus through lysosomal pathways,
instead routing the virus core through late endosomes, which can
give rise to productive infection. For example, studies by Marechal et
al. showed that macrophages take up viral particles bound to the cell
surface through macropinocytosis (Marechal et al., 2001). Shortly
after exposure of macrophages to HIV (independent of viral
envelope–receptor interactions), viral particles were visualized in
intracellular vesicles. While most X4 and all Env-deleted virions
were subsequently degraded, virions with R5-tropic envelopes
achieve virus fusion, leading to capsular release into the cytoplasm
and productive infection (Marechal et al., 2001). Although early
studies indicated that HIV infection is pH-independent and does not
require endocytosis of the CD4 receptor (Maddon et al., 1988;
McClure et al., 1988; Stein et al., 1987), HIV can enter throughclathrin-coated vesicles which fuse with endosomal membranes
(Bourinbaiar et al., 1991; Grewe et al., 1990; Pauza et al., 1988). CD4+
HeLa cell line endocytosis was shown to contribute to HIV entry
using trans dominant-negative mutants of dynamin and Eps15,
which are required for endocytosis. Inhibition was shown by analysis
of reverse transcription products by real-time PCR and by entry by
delivery of virion-associated Vpr-β-galactosidase fusion protein
(Daecke et al., 2005), whereas dynamin is essential for both clathrin-
and caveolar-dependent transport. The trans dominant-negative
mutants decreased HIV entry up to 95%, conﬁrming a role for
endocytosis in productive infection. Expression of dominant-nega-
tive variants Eps15 is speciﬁc for inhibition of clathrin-dependent
endocytosis.
Another important difference between macrophages or tropho-
blasts and T cells or cell lines is the density of CD4 expression. As
calculated by quantitative ﬂow cytometry (QFACS), CD4 binding sites
were estimated to number only about 200/cell on monocytes, as
compared with 5000/cell on primary T cells and T cell lines (Lee et al.,
1999). The relatively low density of CD4 may limit infectibility of
primary macrophages by some virus strains, as well as the effects of
CD63 antibody. CD63 may fulﬁll requirements for HIV entry into cells
with relatively low CD4 expression.
Inhibition of infection of U373-MAGI cells by CD63 siRNA
treatment (Fig. 6A) suggests a more fundamental role for CD63 in
HIV replication in addition to the previously described role at the level
of virus entry into macrophages. In the cell line U373-MAGI-CCR5 or
U373-MAGI-CXCR4, cells are stably transfected with an LTR-β-
galactosidase construct that allows quantitative assessment of HIV
replication based on Tat production. Tat is an early protein, expressed
prior to expression of structural genes, and therefore, decreased β-
galactosidase production in siRNA-treated cells indicates a block to
HIV replication in a step prior to initial HIV translation events. Using a
similar detection system, in this case using cells stably transfected
with LTR-luciferase, down regulation of Rab9, known to be necessary
for transport of cargo proteins from the late endosome to the trans-
Golgi, no effects are seen since this intracellular protein trafﬁcking
occurs after expression of Tat (Murray et al., 2005). Therefore, the
effects of CD63 appear to occur during very early viral translation,
prior to production of the structural genes.
The role of CD63 in post-entry HIV replication events is reinforced
by data in primary macrophages, in which extracellular virus
production is inhibited in cells in which RNAi via CD63-speciﬁc
siRNA transfection 3 days after infection still inhibits HIV replication
(Fig. 2B). Although this was not tested in a single cycle infection
system, reverse transcription proceeds over 48 h in macrophages
(O'Brien et al., 1994), and the effects were tested 7 days later. This
measurement of virus production would be just 1 day after maximal
CD63 down regulation, and demonstrating effects in later stages of
HIV replication in macrophages. The lack of effect with CD4 down
regulation in parallel helps deﬁne the speciﬁcity of the effect, and
supports a role in late replication events, at least after integration.
This was shown by viral inhibition in a CD63-depleted promonocyte
cell line that expresses HIV-1 from stably integrated provirus (Fig. 3).
There are important differences in late replication events in
macrophages, as compared with other HIV target cells. Although
virus production in T cells and cultured cell lines is thought to occur
as result of budding through the plasma cell membrane in T cells
(Garrus et al., 2001), virus assembly in macrophages appears to occur
on a subset of endocytic organelles that carry markers found in late
endosomes of multivesicular bodies (MVBs), most notably CD63
(Pelchen-Matthews et al., 2003). Electron microscopy and immuno-
precipitation experiments suggest that virus release from macro-
phages involves initial budding into endosomal organelles, which are
then are released by fusion of these organelles with the plasma
membrane (Raposo et al., 2002; Pelchen-Matthews et al., 2003;
Kramer et al., 2005). Nonetheless, despite different modes of egress
195H. Chen et al. / Virology 379 (2008) 191–196between macrophages and T cells, events prior to virus assembly and
budding into MVBs require CD63, and are affected by CD63 down
regulation.
Although virus maturation and extracellular release mechanisms
appear to differ between macrophages and T cells or cell lines, CD63
appears to be involved in late replication events in all cell types tested.
It is likely that CD63 is involved with virus protein processing and
possibly in the process by which virus is released. Further studies are
required to delineate the precise role of CD63 in HIV infection of
phagocytic and non-phagocytic cells, especially in virus protein
transportation both after entry and before virus production.
Materials and methods
Cells and viruses
Primary macrophages were puriﬁed from peripheral blood mono-
nuclear cells by adherence to plastic tissue culture dishes. Brieﬂy,
primary monocyte-derived macrophages were isolated from healthy
HIV-1-negative blood donors by Ficoll–Hypaque centrifugation
followed by adherence for 7 days to plastic petri dishes initially
coated with human AB serum. Previously this was shown to yield cells
with N98% esterase positivity (Rich et al., 1992). During differentia-
tion, macrophages were cultured in Iscove's modiﬁed Dulbecco's
medium supplemented with 20% fetal calf serum. U373 cells, obtained
through the NIH AIDS Research and Reference Reagent Program
(contributed by Dr. Michael Emerman and Dr. Adam Geballe), are a
cell line derived from a glioblastoma that has been modiﬁed by stable
transfection of LTR-β-galactosidase (U373-MAGI) (Vodicka et al.,
1997; Harrington et al., 1993). U373-MAGI cells were stably
transfected with either CCR5 or CXCR4 to enable infection by HIV
(Vodicka et al., 1997). Cells were propagated in DMEM and 10% fetal
calf serum.
U1/HIV-1 cells (1×106) obtained from the NIH AIDS Research and
Reference Reagent Program (Folks et al., 1988) were plated in 24-well
microtiter plates on day 1. Cells were transfected with siRNA (200 nM
ﬁnal concentration) using Oligofectamine (Invitrogen) following the
manufacturer's instructions. Complete cell media (RPMI 1640 contain-
ing 2.0 mM L-glutamine; 10% heat-inactivated fetal bovine serum)was
changed after 24 h. Forty-eight hours post-transfection (day 3),
complete RPMI media plus phorbol 12-myristate 13-acetate (PMA)
was added to cells. Extracellular virus was measured in the culture
supernatant on day 5 by p24 ELISA.
Viruses and antibodies
The following HIV-1 strains were obtained from the NIH AIDS
Research and Reference Reagent Program: R5 HIV strains SF162
(Shioda et al., 1991), contributed by Cecilia Cheng-Mayer and ADA
(Westervelt et al., 1992) contributed by Howard Gendelman, R5X4 HIV
strain 89.6 (Collman et al., 1992) contributed by Ron Collman, and X4
HIV strain 92HT599, contributed by Neal Halsey. All HIV-1 stocks
containing HIV p24 200 ng/ml, were further expanded in 40×106
phytohemagglutin antigen (PHA)-stimulated peripheral blood lym-
phocytes (PBLs). Supernatants were harvested 6, 7, and 8 days after
infection, and virus production was determined by p24 antigen
capture assay (Immunodiagnostics). PHA-stimulated PBLs were
propagated in 80% RPMI 1640 (Cellgro), 20% fetal bovine serum, 1%
L-glutamine, 1% penicillin/streptomycin, and 20 U/ml IL-2. All
antibodies used in infection assays were dialyzed before use to
remove sodium azide. Anti-CD4 (Leu3a) antibody was obtained from
BD Biosciences and anti-CD63 antibody (CLB-gran12) was obtained
from Caltag. For ﬂow cytometry studies, ﬂuorescein isothiocyanate
(FITC/phycoerythrin (PE)-labeled anti-CD4 antibody, anti-CD63 anti-
body, and matching mouse immunoglobulin G1 (IgG1) isotype (BD
Immunocytometry Systems mA6 were used.HIV infection assays
HIV-1 stocks were titered, and for most experiments, the inoculum
was 2 ng per 5×104 cells (MOI 0.02). U373-MAGI cells (1×104) were
plated in 96-well microtiter plates the day before infection. After 2 h
incubation of virus supernatant (50 μl/well) at 37 °C, fresh medium
(150 μl) was added to each well. β-galactosidase activity was
measured 48 h after infection using standard protocol (Invitrogen).
Primary macrophages adherent for 7 days were infected 1 day after
plating at 5×104 cells per well in 96-well microtiter plates, with an
approximate MOI of 0.02 in 50 μl/well, with fresh medium (150 μl)
added to each well after 2 h incubation. Cells were fed with fresh
medium 4 days later, and supernatant was assessed for p24 by ELISA
on day 7 post-infection.
Cell surface protein expression and HIV replication in siRNA-transfected
cells
The CD63-speciﬁc target siRNA was designed and synthesized by
Dharmacon. siRNA was delivered intracellularly using Oligofectamine
(Invitrogen) following the manufacturer's instructions. Primary
macrophages adherent for 5 days were transfected with 100 nM
siRNA using oligofectamine (siRNA:oligofectamine=1:1) in serum free
Iscove's medium after plating at 4×105 cells per well in 24-well plates.
Cells were fed with Iscove's medium and 20% FCS after 4 h to
terminate transfection. To measure protein down regulation, cells
were subjected post-infection to ﬂow cytometry for surface protein
analysis or were lysed after 2 days by 1% Triton X-100 in PBS for
Western blot analysis. Primary macrophages were infected with HIV
2 days after siRNA transfection in Iscove's medium at an MOI of
approximately 0.02. Cells were fed with Iscove's medium and 20% FCS
4 days later, and supernatants were harvested and diluted for p24
ELISA on day 7 post-infection.
U373-MAGI cells were transfected with 100 nM siRNA 1 day after
plating at 1×104 cells per well in 96-well microtiter plates. Protein
down regulation was assessed 24 h and 48 h after siRNA transfection
by lysis with 1% Triton X-100 in PBS for Western dot-blot analysis, or
subjected to ﬂow cytometry for surface protein analysis. β-galactosi-
dase activity was measured 48 h after infection using standard
protocol (Invitrogen).
Flow cytometry
U373-MAGI cells were washed twice with PBS and scraped into
Falcon 2054 tubes, 5×105 cells per tube in 100 μl cold PBS (with 5%
serum). Fluorescent antibodies (anti-CD4-PE antibody; anti-CCR5-PE
antibody, and antiCD63-PE antibody) were added to each tube
according to the manufacturer's protocol, and were incubated for
20 min on ice. After staining, cells were washed twice with 4 ml cold
PBS (with 5% serum), and resuspended in 150 μl cold PBS. Cells were
ﬁxed with 150 μl 4% paraformaldehyde and analyzed by ﬂow
cytometry. An anti-IgG1 isotype control antibody was used in all
ﬂow cytometry experiments.
Statistical method
Statistical comparisons among differently treated groups were
made using one-way ANOVA with post hoc Newman-Keuls multiple
comparison test.Acknowledgments
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